Irinotecan for Previously Treated, Advanced, Non-Small Cell Lung Cancer
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01607554 |
Recruitment Status :
Terminated
(Inadequate enrollment (2 subjects in 4 years))
First Posted : May 30, 2012
Results First Posted : April 13, 2018
Last Update Posted : May 22, 2018
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Non-small Cell Lung Cancer | Drug: Irinotecan | Phase 1 Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 2 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Pilot, Non-Randomized Phase II Protocol of Irinotecan for Patients With Previously Treated, Advanced, Non-Small Cell Lung Cancer With High ISG 15 Expression |
Study Start Date : | April 2012 |
Actual Primary Completion Date : | March 2013 |
Actual Study Completion Date : | March 2013 |

Arm | Intervention/treatment |
---|---|
Experimental: Irinotecan
The starting dose of irinotecan for the study is 180 mg/m2, given intravenously every 14 days. Each 14 day period will constitute one cycle of treatment.
|
Drug: Irinotecan
180 mg/m2 Irinotecan intravenously over 60 minutes on day 1 of each cycle Pre-medication for irinotecan: palonosetron 0.25 mg and dexamethasone 8 - 16 mg, both administered intravenously. Atropine 0.25 - 0.5 mg subcutaneously or IV is at the discretion of the treating physician Other Name: Camptosar; Campto |
- Tumor Response [ Time Frame: 8 weeks ]Change in tumor size will be measured by CT scan using RECIST criteria.
- Time to Progression (TTP) [ Time Frame: Up to 100 months ]Time to progression will be measured from the time of first treatment until there is evidence of progressive disease or death, from the date of first documented progression or date of death from any cause, whichever occurs first, assessed up to 100 months. Death will be treated as a progression event.
- Retrospectively Evaluate the Role of Tumor SULF2 Gene Methylation Status in Treatment Efficacy [ Time Frame: 1 year ]Patients who have a loss of SULF2 gene expression have a better outcome than those whose tumors express SULF2. High level of ISG15 expression in NSCLC may indicate a subgroup of tumors that may be more sensitive to the cytotoxic effects of irinotecan. In patients who consent to screening, 10 unstained slides of archived diagnostic tissue will be obtained from formalin-fixed, paraffin-embedded specimens and analyzed in the laboratories of our Lovelace Respiratory Research Institute co-investigators.
- Toxicity of Irinotecan Salvage Chemotherapy [ Time Frame: 2 days preceding each cycle of therapy ]Use blood samples to measure possible 1) Neutropenia, 2) Thrombocytopenia, 3)Diarrhea; 4) Other measures of toxicity other than alopecia, anorexia, and asthenia as listed in the National Cancer Institute Common Toxicity Criteria v. 4.03
- Progression Free Survival (PFS) [ Time Frame: Up to 100 months ]
- Median Duration of Response [ Time Frame: Up to 100 months ]
- Median Overall Survival (OS) [ Time Frame: 100 months ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
-INCLUSION:
18 years of age or older Have received prior chemotherapy for histologically proven advanced non-small cell lung cancer, up to 3 prior treatments Tumors display high ISG15 (ISG15H) at screening Life expectancy of at least 12 weeks ECOG/Zubrod performance status of 0-2 Provide informed consent permission to participate
Adequate bone marrow function as follows:
1. Absolute neutrophil count of greater than or equal to 1,500 or cells/mm3, and 2) Platelet count greater than or equal to 100,000/mm3 and 3) Absence of a regular red blood cell transfusion requirement
Adequate hepatic function with:
- Total bilirubin less than or equal to 4.0 mg/dl, and
- SGOT or SGPT less than or equal to four times ULN
Adequate renal function as defined by:
1) Serum creatinine less than or equal to 1.5 x ULN
Exclusion Criteria:
Symptomatic brain metastases
Pregnant women or nursing mothers
Patients of child bearing potential must use adequate contraception.
May not be receiving other concurrent chemotherapy or radiation therapy
Severe medical problems such as uncontrolled diabetes mellitus or cardiovascular disease or active infections
Previous hypersensitivity reaction to camptothecins

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01607554
United States, New Mexico | |
Hematology Oncology Associates | |
Albuquerque, New Mexico, United States, 87106 | |
University of New Mexico Cancer Center | |
Albuquerque, New Mexico, United States, 87131 | |
New Mexico Cancer Care Associates | |
Santa Fe, New Mexico, United States, 87505 |
Principal Investigator: | Martin J Edelman, MD | UNM Cancer Center | |
Principal Investigator: | Mathewos Tessema, PhD | Lovelace Respiratory Research Institute |
Responsible Party: | New Mexico Cancer Care Alliance |
ClinicalTrials.gov Identifier: | NCT01607554 |
Other Study ID Numbers: |
INST 1201 NCI-2012-01531 ( Registry Identifier: NCI CTRP ) |
First Posted: | May 30, 2012 Key Record Dates |
Results First Posted: | April 13, 2018 |
Last Update Posted: | May 22, 2018 |
Last Verified: | March 2018 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Lung non small cell NSCLC Irinotecan |
Lung Neoplasms Carcinoma, Non-Small-Cell Lung Respiratory Tract Neoplasms Thoracic Neoplasms Neoplasms by Site Neoplasms Lung Diseases Respiratory Tract Diseases |
Carcinoma, Bronchogenic Bronchial Neoplasms Irinotecan Topoisomerase I Inhibitors Topoisomerase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Antineoplastic Agents |